Fact CheckerSign in

NCT05825404Completed

Smart Lighting for Nursing Home Residents With Dementia

The Effect of Smart Ambient Bright Light for Nursing Home Residents With Alzheimer's Disease and Related Dementias

Source: ClinicalTrials.gov · Last updated 8 Aug 2025

Brief summary (registry, in English)

This proposed study seeks to develop a smart ambient bright light (SABL) intervention to provide auto-controlled, consistent indoor lighting that incorporates natural daylight. This SABL includes tunable LED lights, photosensors, and controllers. The SABL system has a pre-programmed 24-hour control schedule for illuminance settings to mimic the natural bright-dark cycle. It will automatically adjust the lights to accommodate the daylight effect to minimize staff burden and maximize the LI effect. The SABL will be installed in participants' bedrooms and designated areas in the dining rooms and activity rooms for four weeks. Each participant will wear a personal light monitor to measure the lighting dosage each participant receives. This study will address three aims: 1) pilot test the effect of SABL on reducing agitation in persons with ADRD, 2) evaluate the fidelity of the SABL delivery, and 3) evaluate the feasibility of implementing the SABL. The study will be conducted in two NHs in Pennsylvania. For aims 1 and 2, the investigators will use a crossover, cluster randomized control trial (RCT) and will enroll residents with ADRD and agitation. For aim 3, the investigators will use a mixed methods design and will interview NH stakeholders to evaluate the acceptability, feasibility, and appropriateness of the intervention. This is the first study that incorporates daylight in ambient light interventions and the first study that addresses the measurement, feasibility, and fidelity of lighting interventions. Findings will establish evidence-based implementation strategies and the best design for SABL to reduce agitation for persons with ADRD in NHs.

Status (registry)
Completed
Study type
Interventional
Enrollment
51 (actual)
First submitted
28 Mar 2023
Start date
24 Apr 2023
Primary completion date
30 Oct 2023
Lead sponsor
Penn State University
NCT number
NCT05825404

What you commit to

  • Study type: Interventional
  • Participants enrolled: 51
  • From 24 Apr 2023 to the primary completion date, 30 Oct 2023
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Major mental illness
  • Severe vision impairment
  • Severe acute or terminal illness
    • Staff participants:

Other

  • Major sleep problems

Who the study is looking for

  • Age≥55
  • English speaking
  • Nursing home residency≥3 months
  • Clinical Diagnosis of Alzheimer's Disease and related dementia
  • Presence of agitation over the past week
  • Age≥18
  • English speaking
  • Employed as a certified nurse assistant (CNA), activity staff, nurse, director of nursing (DON), director of maintenance, administer or other leadership position for at least 3 months. The CNA, activity staff, and nurse must have direct care interactions with the resident participant(s).

Criteria the registry did not label

  • Resident participants

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Valley View Retirement Community
Coordinator of this site? Confirm its status
BellevilleUnited StatesUnknown status
Christ the King Manor
Coordinator of this site? Confirm its status
DuBoisUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.